Loading clinical trials...
Loading clinical trials...
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Highlands Oncology Group
Springdale, Arkansas, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States
Rocky Mountain Cancer Centers, LLP
Denver, Colorado, United States
City Of Hope - Chicago
Zion, Illinois, United States
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Texas Oncology - Central South
Austin, Texas, United States
Texas Oncology - Gulf Coast
Houston, Texas, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Start Date
February 10, 2026
Primary Completion Date
November 2, 2027
Completion Date
November 1, 2028
Last Updated
March 2, 2026
224
ESTIMATED participants
PF-08634404
BIOLOGICAL
Combination 1
DRUG
Combination 2
DRUG
Lead Sponsor
Pfizer
NCT00026884
NCT05225428
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions